Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice

In conclusion, FVD showed efficacy in a heavily pretreated, high‐risk multiple myeloma population with a high degree of patients refractory to novel agents including PIs.

Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Marc ‐Andrea Baertsch, Jens Hillengass, Joanna Blocka, Stefan Schönland, Ute Hegenbart, Hartmut Goldschmidt, Marc S. Raab Tags: ORIGINAL RESEARCH ARTICLE Source Type: research